{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:34:40Z","timestamp":1794620080821,"version":"4.9.1"},"reference-count":36,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Patients treated for classic Hodgkin lymphoma (CHL) have a reported 13-fold increased risk of developing subsequent non-Hodgkin lymphoma (NHL). In light of the growing awareness of CHL mimickers, this study re-assesses this risk based on an in-depth pathology review of a nationwide cohort of patients diagnosed with CHL in the Netherlands (2006-2013) and explores the spectrum of CHL mimickers. Among 2,669 patients with biopsy-proven CHL, 54 were registered with secondary NHL. On review, CHL was confirmed in 25\/54 patients. In six of these, the subsequent lymphoma was a primary mediastinal B-cell lymphoma\/mediastinal gray zone lymphoma, biologically related to CHL and 19\/25 were apparently unrelated B-cell NHL. In 29\/54 patients, CHL was reclassified as NHL, including T-cell lymphomas with secondary Hodgkin-like B-blasts (n=15), Epstein Barr virus-positive diffuse large B-cell lymphoma (n=8), CD30+ T-cell lymphoma (n=3) and indolent B-cell proliferations (n=3). Higher age, disseminated disease at presentation, extensive B-cell marker expression and association with Epstein-Barr virus were identified as markers to alert for CHL mimickers. Based on these data, the risk of developing NHL after CHL treatment was re-calculated to 3.6-fold (standardized incidence ratio 3.61; confidence interval: 2.29-5.42). In addition, this study highlights the clinicopathological pitfalls leading to misinterpretation of CHL and consequences for the care of individual patients, interpretation of trials and epidemiological assessments.<\/jats:p>","DOI":"10.3324\/haematol.2022.280840","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T05:02:29Z","timestamp":1666242149000},"page":"1349-1358","source":"Crossref","is-referenced-by-count":6,"title":["Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies"],"prefix":"10.3324","volume":"108","author":[{"given":"Max V.","family":"Boot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schaapveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther C.","family":"Van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie J.","family":"Hijmering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PALGA","family":"Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Van der Oord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora E.","family":"Van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash G.","family":"Dinmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne","family":"Koens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"47546","doi-asserted-by":"crossref","unstructured":"Driessen J, Visser O, Zijlstra JM. Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017. Leukemia. 2021; 35(2):494-505.","DOI":"10.1038\/s41375-020-0875-0"},{"key":"47547","doi-asserted-by":"crossref","unstructured":"Schaapveld M, Aleman BM, van Eggermond AM. Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma. N Engl J Med. 2015; 373(26):2499-2511.","DOI":"10.1056\/NEJMoa1505949"},{"key":"47548","doi-asserted-by":"crossref","unstructured":"Dores GM, Metayer C, Curtis RE. Second malignant neoplasms among long-term survivors of Hodgkin\u2019s disease: a population-based evaluation over 25 years. J Clin Oncol. 2002; 20(16):3484-3494.","DOI":"10.1200\/JCO.2002.09.038"},{"key":"47549","doi-asserted-by":"crossref","unstructured":"Swerdlow AJ, Higgins CD, Smith P. Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study. J Clin Oncol. 2011; 29(31):4096-4104.","DOI":"10.1200\/JCO.2011.34.8268"},{"key":"47550","doi-asserted-by":"crossref","unstructured":"Chihara D, Dores G, Flowers C, Morton LM. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood. 2021; 138(9):785-789.","DOI":"10.1182\/blood.2020010497"},{"key":"47551","doi-asserted-by":"crossref","unstructured":"Bell D, Gaillard F. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. 2010.","DOI":"10.53347\/rID-9250"},{"key":"47552","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Stein H. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84(5):1361-1392.","DOI":"10.1182\/blood.V84.5.1361.bloodjournal8451361"},{"key":"47553","doi-asserted-by":"crossref","unstructured":"Kritharis A, Pilichowska M, Evens AM. How I manage patients with grey zone lymphoma. Br J Haematol. 2016; 174(3):345-350.","DOI":"10.1111\/bjh.14174"},{"key":"47554","doi-asserted-by":"crossref","unstructured":"Sarkozy C, Chong L, Takata K. Gene expression profiling of gray zone lymphoma. Blood Adv. 2020; 4(11):2523-2535.","DOI":"10.1182\/bloodadvances.2020001923"},{"key":"47555","doi-asserted-by":"crossref","unstructured":"Sarkozy C, Hung SS, Chavez EA. Mutational landscape of gray zone lymphoma. Blood. 2021; 137(13):1765-1776.","DOI":"10.1182\/blood.2020007507"},{"key":"47556","doi-asserted-by":"crossref","unstructured":"Attygalle AD, Cabecadas J, Gaulard P. Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward -report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology. 2014; 64(2):171-199.","DOI":"10.1111\/his.12251"},{"key":"47557","doi-asserted-by":"crossref","unstructured":"Br\u00f6ckelmann PJ, Goergen H, Fuchs M. Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group. Br J Haematol. 2015; 171(4):547-556.","DOI":"10.1111\/bjh.13646"},{"key":"47558","doi-asserted-by":"crossref","unstructured":"Hartmann S, Goncharova O, Portyanko A. CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma. Mod Pathol. 2019; 32(1):37-47.","DOI":"10.1038\/s41379-018-0108-5"},{"key":"47559","doi-asserted-by":"crossref","unstructured":"Nicolae A, Pittaluga S, Venkataraman G. Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin\/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. Am J Surg Pathol. 2013; 37(6):816-826.","DOI":"10.1097\/PAS.0b013e3182785610"},{"key":"47560","doi-asserted-by":"crossref","unstructured":"de Jong D, Roemer MG, Chan JK. B-cell and classical Hodgkin lymphomas associated with immunodeficiency: 2015 SH\/EAHP Workshop Report-Part 2. Am J Clin Pathol. 2017; 147(2):153-170.","DOI":"10.1093\/ajcp\/aqw216"},{"key":"47561","doi-asserted-by":"crossref","unstructured":"Natkunam Y, Gratzinger D, Chadburn A. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?. Blood. 2018; 132(18):1871-1878.","DOI":"10.1182\/blood-2018-04-842559"},{"key":"47562","doi-asserted-by":"crossref","unstructured":"Pitman SD, Huang Q, Zuppan CW. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol. 2006; 30(4):470-476.","DOI":"10.1097\/00000478-200604000-00007"},{"key":"47563","doi-asserted-by":"crossref","unstructured":"Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES. Diagnosis of Hodgkin lymphoma in the modern era. Br J Haematol. 2019; 184(1):45-59.","DOI":"10.1111\/bjh.15614"},{"key":"47564","doi-asserted-by":"crossref","unstructured":"Casparie M, Tiebosch AT, Burger G. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007; 29(1):19-24.","DOI":"10.1155\/2007\/971816"},{"key":"47565","doi-asserted-by":"crossref","unstructured":"Kersten MJ, Driessen J, Zijlstra JM. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study. Haematologica. 2021; 106(4):1129-1137.","DOI":"10.3324\/haematol.2019.243238"},{"key":"47566","doi-asserted-by":"crossref","unstructured":"Langerak AW, Groenen PJ, Bruggemann M. EuroClonality\/BIOMED-2 guidelines for interpretation and reporting of Ig\/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012; 26(10):2159-2171.","DOI":"10.1038\/leu.2012.246"},{"key":"47567","doi-asserted-by":"crossref","unstructured":"Sie D, Snijders PJ, Meijer GA. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol. 2014; 37(5):353-361.","DOI":"10.1007\/s13402-014-0196-2"},{"key":"47568","unstructured":"Breslow NE, Day NE. Statistical methods in cancer research. Volume II--the design and analysis of cohort studies. IARC Sci Publ. 1987; 82:1-406."},{"key":"47569","doi-asserted-by":"crossref","unstructured":"Laurent C, Baron M, Amara N. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath network. J Clin Oncol. 2017; 35(18):2008-2017.","DOI":"10.1200\/JCO.2016.71.2083"},{"key":"47570","doi-asserted-by":"crossref","unstructured":"Gratzinger D, de Jong D, Jaffe ES. T- and NK-cell lymphomas and systemic lymphoproliferative disorders and the immunodeficiency setting: 2015 SH\/EAHP Workshop Report-Part 4. Am J Clin Pathol. 2017; 147(2):188-203.","DOI":"10.1093\/ajcp\/aqw213"},{"key":"47571","doi-asserted-by":"crossref","unstructured":"Xu Y, McKenna RW, Hoang MP, Collins RH, Kroft SH. Composite angioimmunoblastic T-cell lymphoma and diffuse large B-cell lymphoma: a case report and review of the literature. Am J Clin Pathol. 2002; 118(6):848-854.","DOI":"10.1309\/VD2D-98ME-MB3F-WH34"},{"key":"47572","doi-asserted-by":"crossref","unstructured":"Eberle FC, Salaverria I, Steidl C. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol. 2011; 24(12):1586-1597.","DOI":"10.1038\/modpathol.2011.116"},{"key":"47573","doi-asserted-by":"crossref","unstructured":"Green MR, Monti S, Rodig SJ. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116(17):3268-3277.","DOI":"10.1182\/blood-2010-05-282780"},{"key":"47574","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Wright G, Leroy K. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003; 198(6):851-862.","DOI":"10.1084\/jem.20031074"},{"key":"47575","doi-asserted-by":"crossref","unstructured":"Savage KJ, Monti S, Kutok JL. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003; 102(12):3871-3879.","DOI":"10.1182\/blood-2003-06-1841"},{"key":"47576","doi-asserted-by":"crossref","unstructured":"Liu PP, Wang KF, Xia Y. Racial patterns of patients with primary mediastinal large B-cell lymphoma. Medicine (Baltimore). 2016; 95(27):1-7.","DOI":"10.1097\/MD.0000000000004054"},{"key":"47577","doi-asserted-by":"crossref","unstructured":"Traverse-Glehen A, Pittaluga S, Gaulard P. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin\u2019s lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005; 29(11):1411-1421.","DOI":"10.1097\/01.pas.0000180856.74572.73"},{"key":"47578","doi-asserted-by":"crossref","unstructured":"K\u00fcppers R, D\u00fchrsen U, Hansmann ML. Pathogenesis, diagnosis, and treatment of composite lymphomas. Lancet Oncol. 2014; 15(10):e435-e446.","DOI":"10.1016\/S1470-2045(14)70153-6"},{"key":"47579","doi-asserted-by":"crossref","unstructured":"Dobson R, Du PY, R\u00e1s\u00f3-Barnett L. Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis. Haematologica. 2022; 107(2):489-499.","DOI":"10.3324\/haematol.2020.265991"},{"key":"47580","doi-asserted-by":"crossref","unstructured":"Crombie JL, LaCasce AS. Epstein Barr virus associated B-cell lymphomas and iatrogenic lymphoproliferative disorders. Front Oncol. 2019; 9:109.","DOI":"10.3389\/fonc.2019.00109"},{"key":"47581","doi-asserted-by":"crossref","unstructured":"Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 2017; 129(9):1095-1102.","DOI":"10.1182\/blood-2016-09-692541"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.280840\/74938","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.280840\/75573","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10838\/74938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:37Z","timestamp":1794045757000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.280840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.280840","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}